Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for OptimizeRx (OPRX) over the last 14 years, with FY2024 value amounting to -$4.9 million.

  • OptimizeRx's Cash from Financing Activities rose 5150.38% to -$258000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.9 million, marking a year-over-year decrease of 11771.18%. This contributed to the annual value of -$4.9 million for FY2024, which is 11740.26% down from last year.
  • As of FY2024, OptimizeRx's Cash from Financing Activities stood at -$4.9 million, which was down 11740.26% from $28.2 million recorded in FY2023.
  • In the past 5 years, OptimizeRx's Cash from Financing Activities registered a high of $73.9 million during FY2021, and its lowest value of -$19.0 million during FY2022.
  • Over the past 5 years, OptimizeRx's median Cash from Financing Activities value was -$1.9 million (recorded in 2020), while the average stood at $15.3 million.
  • Per our database at Business Quant, OptimizeRx's Cash from Financing Activities skyrocketed by 398916.38% in 2021 and then plummeted by 12563.52% in 2022.
  • Annual analysis of 5 years shows OptimizeRx's Cash from Financing Activities stood at -$1.9 million in 2020, then soared by 3989.16% to $73.9 million in 2021, then tumbled by 125.64% to -$19.0 million in 2022, then skyrocketed by 248.91% to $28.2 million in 2023, then crashed by 117.4% to -$4.9 million in 2024.
  • Its Cash from Financing Activities stands at -$4.9 million for FY2024, versus $28.2 million for FY2023 and -$19.0 million for FY2022.